Obstet Gynecol 2021 May 6. Epub 2021 May 6.
Department of Prevention, the Department of Gynecological Oncology, the Department of Pathology, and the Research and Teaching Institute, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; the Department of Gynecologic Oncology and Reproductive Medicine, the University of Texas MD Anderson Cancer Center, Houston, Texas; the Department of Obstetrics and Gynecology, Federal University of Health Sciences of Porto Alegre/Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil; and the Teaching Superintendence, A.C. Camargo Cancer Center, São Paulo, Brazil.
Objective: To evaluate the histologic response rate of high-grade squamous intraepithelial lesions (HSIL) of the cervix after topical application of 5% imiquimod cream.
Methods: In this phase II trial, women with cervical HSIL (cervical intraepithelial neoplasia [CIN] 2-3) were randomly assigned to 250 mg of 5% imiquimod cream applied to the cervix weekly for 12 weeks, followed by loop electrosurgical excision procedure (LEEP) without preceding treatment. The sample size was calculated based on the HSIL regression rates previously reported by Grimm et al. Read More